Concepts (88)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 3 | 2020 | 179 | 1.210 |
Why?
|
| Lung Neoplasms | 3 | 2020 | 423 | 0.660 |
Why?
|
| Mass Screening | 3 | 2019 | 256 | 0.630 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 100 | 0.610 |
Why?
|
| Preventive Health Services | 1 | 2020 | 39 | 0.610 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 28 | 0.610 |
Why?
|
| Holidays | 1 | 2019 | 4 | 0.600 |
Why?
|
| Access to Information | 1 | 2019 | 13 | 0.580 |
Why?
|
| Internal Medicine | 1 | 2019 | 53 | 0.580 |
Why?
|
| Continuity of Patient Care | 1 | 2019 | 73 | 0.560 |
Why?
|
| Patient Readmission | 1 | 2019 | 135 | 0.550 |
Why?
|
| Bradycardia | 1 | 2016 | 17 | 0.470 |
Why?
|
| Mortality | 1 | 2016 | 122 | 0.440 |
Why?
|
| Documentation | 2 | 2019 | 39 | 0.300 |
Why?
|
| Aged | 8 | 2020 | 10265 | 0.290 |
Why?
|
| Middle Aged | 9 | 2020 | 11853 | 0.280 |
Why?
|
| Oxymorphone | 2 | 2018 | 9 | 0.270 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2018 | 30 | 0.260 |
Why?
|
| Decision Making | 2 | 2019 | 189 | 0.260 |
Why?
|
| Opioid-Related Disorders | 2 | 2018 | 68 | 0.250 |
Why?
|
| Analgesics, Opioid | 2 | 2018 | 252 | 0.230 |
Why?
|
| Humans | 12 | 2020 | 32284 | 0.210 |
Why?
|
| Echocardiography | 2 | 2016 | 190 | 0.210 |
Why?
|
| Male | 8 | 2020 | 19443 | 0.210 |
Why?
|
| Female | 8 | 2020 | 19947 | 0.210 |
Why?
|
| United States | 4 | 2020 | 4072 | 0.180 |
Why?
|
| Risk Factors | 3 | 2019 | 3934 | 0.170 |
Why?
|
| North Carolina | 3 | 2019 | 1300 | 0.170 |
Why?
|
| Adult | 5 | 2019 | 9259 | 0.160 |
Why?
|
| Hispanic Americans | 2 | 2016 | 772 | 0.160 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 3902 | 0.160 |
Why?
|
| Eligibility Determination | 1 | 2020 | 18 | 0.160 |
Why?
|
| History, 21st Century | 1 | 2020 | 62 | 0.150 |
Why?
|
| Advance Care Planning | 1 | 2019 | 15 | 0.150 |
Why?
|
| User-Computer Interface | 1 | 2019 | 54 | 0.140 |
Why?
|
| Medicare | 1 | 2020 | 219 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 161 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2019 | 112 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 130 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2019 | 308 | 0.130 |
Why?
|
| Young Adult | 3 | 2019 | 2649 | 0.130 |
Why?
|
| Internet | 1 | 2019 | 202 | 0.130 |
Why?
|
| Patient Selection | 1 | 2019 | 272 | 0.130 |
Why?
|
| Time Factors | 2 | 2019 | 2205 | 0.130 |
Why?
|
| Hepatitis C | 1 | 2017 | 47 | 0.130 |
Why?
|
| Retrospective Studies | 4 | 2019 | 3628 | 0.130 |
Why?
|
| Patient Admission | 1 | 2017 | 54 | 0.120 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2017 | 63 | 0.120 |
Why?
|
| Adolescent | 3 | 2019 | 3519 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2017 | 121 | 0.120 |
Why?
|
| Heart Atria | 1 | 2016 | 81 | 0.110 |
Why?
|
| Heart Ventricles | 1 | 2016 | 146 | 0.110 |
Why?
|
| Kidney | 1 | 2018 | 521 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2015 | 114 | 0.100 |
Why?
|
| Ethnic Groups | 1 | 2016 | 450 | 0.100 |
Why?
|
| Research Design | 1 | 2015 | 314 | 0.090 |
Why?
|
| Incidence | 1 | 2016 | 1241 | 0.090 |
Why?
|
| Atherosclerosis | 1 | 2016 | 820 | 0.080 |
Why?
|
| Delayed-Action Preparations | 2 | 2018 | 33 | 0.070 |
Why?
|
| Terminal Care | 1 | 2019 | 25 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 110 | 0.040 |
Why?
|
| Patient Participation | 1 | 2019 | 90 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 99 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2018 | 36 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2019 | 413 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 200 | 0.030 |
Why?
|
| Hepatitis C Antibodies | 1 | 2017 | 1 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 24 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2017 | 49 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 239 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2018 | 197 | 0.030 |
Why?
|
| Cellulitis | 1 | 2017 | 12 | 0.030 |
Why?
|
| Endocarditis, Bacterial | 1 | 2017 | 15 | 0.030 |
Why?
|
| Renal Replacement Therapy | 1 | 2017 | 18 | 0.030 |
Why?
|
| Abscess | 1 | 2017 | 28 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 565 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2017 | 56 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 591 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2017 | 98 | 0.030 |
Why?
|
| Bacteremia | 1 | 2017 | 66 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 60 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 955 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 238 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 293 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 907 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2018 | 534 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 1425 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 1840 | 0.020 |
Why?
|